Journal Article
. 2016 Aug; 14(1):223.
doi: 10.1186/s12957-016-0988-0.

Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer

Pattaraporn Wangchinda 1 Suthinee Ithimakin 2 
Affiliations
  • PMID: 27557635
  •     15 References
  •     18 citations

Abstract

Background: Occasionally, breast cancer relapses more than 5 years after initial treatment, sometimes with highly aggressive disease in such late-recurring patients. This study investigated predictors of recurrence after more than 5 years in operable breast cancer.

Methods: We retrospectively analyzed data from patients with recurrent breast cancer treated at Siriraj Hospital. Patients were divided into those whose relapse times were longer or shorter than 5 years. Factors that predicted late recurrence were analyzed in both the overall population and the luminal subgroup. Patterns of relapse, changes in biomarkers, and time to disease progression after first relapse were also recorded.

Results: We included 300 women whose breast cancers recurred between 2005 and 2013, of whom 180 had recurrence within 5 years of diagnosis and 120 later than 5 years (median time to recurrence: 45.43 months; range: 4.4-250.3 months). Tumors larger than 2 cm, lymph node metastasis, and high nuclear grade were related with early recurrence. Estrogen receptor-positive, progesterone receptor-positive, and HER2(-) disease predicted late recurrence. Almost all late-relapsing patients with luminal tumors had high estrogen receptor (ER(+)) titers (≥50 %) and HER2(-) disease. Liver and brain were the most common early recurrence sites. Biomarkers did not significantly change by time of recurrence.

Conclusions: ER(+)/PR(+) and HER2(-) patients have higher risk of recurrence later than 5 years, especially in patients with high ER titer and low nuclear grade. Larger and node-positive tumors had higher risk of early recurrence.

Keywords: Breast cancer; Clinicopathological; Late recurrence; Luminal breast cancer.

Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.
Yi Zhang, Catherine A Schnabel, +7 authors, Mark G Erlander.
Clin Cancer Res, 2013 Jun 13; 19(15). PMID: 23757354
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Paul E Goss, James N Ingle, +16 authors, National Cancer Institute of Canada Clinical Trials Group MA.17.
J Clin Oncol, 2007 Apr 25; 25(15). PMID: 17452676
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
A Goldhirsch, J N Ingle, +4 authors, Panel members.
Ann Oncol, 2009 Jun 19; 20(8). PMID: 19535820    Free PMC article.
Highly Cited.
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
Evaluation of factors related to late recurrence--later than 10 years after the initial treatment--in primary breast cancer.
Reiki Nishimura, Tomofumi Osako, +5 authors, Nobuyuki Arima.
Oncology, 2013 Jul 23; 85(2). PMID: 23867253
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, +22 authors, College of American Pathologists.
J Clin Oncol, 2006 Dec 13; 25(1). PMID: 17159189
Highly Cited.
Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Daniel F Hayes.
Breast, 2015 Aug 05; 24 Suppl 2. PMID: 26238437
The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?
Ian E Smith, Belinda Yeo, Gaia Schiavon.
Am Soc Clin Oncol Educ Book, 2014 May 27;. PMID: 24857098
Review.
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.
Eleftherios P Mamounas, Barry Lembersky, +7 authors, Norman Wolmark.
Clin Breast Cancer, 2007 Jan 24; 7(5). PMID: 17239269
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Christina Davies, Hongchao Pan, +36 authors, Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.
Lancet, 2012 Dec 12; 381(9869). PMID: 23219286    Free PMC article.
Highly Cited.
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
P Dubsky, J C Brase, +18 authors, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Br J Cancer, 2013 Oct 26; 109(12). PMID: 24157828    Free PMC article.
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Factors predicting late recurrence for estrogen receptor-positive breast cancer.
Ivana Sestak, Mitch Dowsett, +4 authors, Jack Cuzick.
J Natl Cancer Inst, 2013 Sep 14; 105(19). PMID: 24029245    Free PMC article.
Highly Cited.
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, +29 authors, Antonio C Wolff.
J Clin Oncol, 2010 Apr 21; 28(16). PMID: 20404251    Free PMC article.
Highly Cited. Systematic Review.
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Paul E Goss, James N Ingle, +15 authors, Dongsheng Tu.
J Clin Oncol, 2008 Mar 12; 26(12). PMID: 18332475
Introducing novel and comprehensive models for predicting recurrence in breast cancer using the group LASSO approach: are estimates of early and late recurrence different?
Majid Akrami, Peyman Arasteh, +5 authors, Abdolrasoul Talei.
World J Surg Oncol, 2018 Sep 14; 16(1). PMID: 30208904    Free PMC article.
Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes.
Sasha Lupichuk, Winson Y Cheung, Douglas Stewart.
Breast Cancer (Auckl), 2019 Oct 23; 13. PMID: 31636482    Free PMC article.
Metabolic consequences of perioperative oral carbohydrates in breast cancer patients - an explorative study.
Tone Hoel Lende, Marie Austdal, +10 authors, Jan P A Baak.
BMC Cancer, 2019 Dec 06; 19(1). PMID: 31801490    Free PMC article.
Risk factors for breast cancer brain metastases: a systematic review.
Lola Koniali, Andreas Hadjisavvas, +8 authors, Kyriacos Kyriacou.
Oncotarget, 2020 Feb 29; 11(6). PMID: 32110283    Free PMC article.
Review.
A conditional model predicting the 10-year annual extra mortality risk compared to the general population: a large population-based study in Dutch breast cancer patients.
Marissa C van Maaren, Robert F Kneepkens, +4 authors, Sabine Siesling.
PLoS One, 2019 Jan 25; 14(1). PMID: 30677053    Free PMC article.
Autologous Fat Grafting Does Not Increase Risk of Oncologic Recurrence in the Reconstructed Breast.
Krishna S Vyas, Ryan C DeCoster, +8 authors, Henry C Vasconez.
Ann Plast Surg, 2020 Feb 13; 84(6S Suppl 5). PMID: 32049757    Free PMC article.
DGM-CM6: A New Model to Predict Distant Recurrence Risk in Operable Endocrine-Responsive Breast Cancer.
Lei Lei, Xiao-Jia Wang, +2 authors, Yunyun Zhou.
Front Oncol, 2020 Jun 13; 10. PMID: 32528885    Free PMC article.
Incidence and Predictors of Recurrence among Breast Cancer Patients in Black Lion Specialized Hospital Adult Oncology Unit, Addis Ababa, Ethiopia: Retrospective Follow-up Study with Survival Analysis.
Wondimeneh Shibabaw Shiferaw, Yared Asmare Aynalem, Tadesse Yirga Akalu, Tefera Mulugeta Demelew.
J Cancer Prev, 2020 Jul 11; 25(2). PMID: 32647652    Free PMC article.
Prognostic Factors of Local-Regional Recurrence in Patients with Operable Breast Cancer in Asia: A Meta-Analysis.
Wirsma Arif Harahap, Ricvan Dana Nindrea.
Open Access Maced J Med Sci, 2019 Mar 22; 7(4). PMID: 30894935    Free PMC article.
Review.
Young Patients with Hormone Receptor-Positive Breast Cancer Have a Higher Long-Term Risk of Breast Cancer Specific Death.
Jianfei Fu, Chenhan Zhong, +5 authors, Jinlin Du.
J Breast Cancer, 2019 Apr 04; 22(1). PMID: 30941237    Free PMC article.
Reirradiation of recurrent breast cancer with proton beam therapy: A case report and literature review.
Yi-Lan Lin.
World J Clin Oncol, 2019 Aug 10; 10(7). PMID: 31396475    Free PMC article.
Potential protein markers for breast cancer recurrence: a retrospective cohort study.
Chunyan He, Rina Plattner, +6 authors, Thomas C Tucker.
Cancer Causes Control, 2018 Nov 30; 30(1). PMID: 30488343    Free PMC article.
Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation.
Molly B Moravek, Rafael Confino, +6 authors, Mary Ellen Pavone.
Breast Cancer Res Treat, 2021 Jan 05; 186(2). PMID: 33392838
Breast cancer: insights in disease and influence of drug methotrexate.
Vítor Yang, Maria João Gouveia, +4 authors, Nuno Vale.
RSC Med Chem, 2021 Jan 23; 11(6). PMID: 33479665    Free PMC article.
Review.
A Clinical Decision Support System for Predicting Invasive Breast Cancer Recurrence: Preliminary Results.
Raffaella Massafra, Agnese Latorre, +13 authors, Vito Lorusso.
Front Oncol, 2021 Mar 30; 11. PMID: 33777733    Free PMC article.
Outcomes After Accelerated Partial Breast Irradiation in Women With Triple Negative Subtype and Other "High Risk" Variables Categorized as Cautionary in The ASTRO Guidelines.
Anabel Goulding, Lina Asmar, +4 authors, Charles Leonard.
Front Oncol, 2021 Mar 30; 11. PMID: 33777758    Free PMC article.
A Clinicogenetic Prognostic Classifier for Prediction of Recurrence and Survival in Asian Breast Cancer Patients.
Ting-Hao Chen, Jun-Ru Wei, +2 authors, Kuan-Hui Shih.
Front Oncol, 2021 Apr 06; 11. PMID: 33816299    Free PMC article.
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis.
Elizabeth M Salvo, Abril Oliva Ramirez, +4 authors, Imtiaz A Samjoo.
Breast, 2021 Mar 08; 57. PMID: 33677313    Free PMC article.